The agonist of TLR7, Imiquimod (also known as R-837) is an immune response modifier and has been approved by U.S. Food and Drug Administration (FDA) for treatment of superficial basal cell carcinoma, genital warts and actinic keratosis.95 In the breast cancer model, Imiquimod in combination with laser irradiation can activate NK cells, macrophages and B lymphocytes via TLR-7 induced cytokines (IFN-α, IL-6 and TNF-α) to further enhance the activation of immune response. Here, TLR7 is linked to breast carcinoma.